E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Medical condition in which the ductus arteriosus fails to close after birth |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10034130 |
E.1.2 | Term | Patent ductus arteriosus |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Our primary objective is to compare the efficacy of early targeted treatment of PDA, in ELBW infants, with intravenous paracetamol administration compared to placebo, in reducing the combined outcomes of PIVH, NEC and death before discharge. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the efficacy of early targeted treatment of PDA, in ELBW infants, with intravenous paracetamol infusion compared with placebo, in preventing or reducing further known complications associated with PDA, as well as recording a number of known variables relating to prematurity from enrolment in the trial until discharge home from the hospital. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- They are inborn or transferred to a participating centre after birth and have a birth weight of <1000g established by weight assessment on admission to NICU. - The treating doctors plan to offer them intensive care. - Large PDA is present on fnECHO, defined as PDA with diameter greater than 1.5mm with non-restrictive flow (defined as diastolic flow less than 50% of systolic flow)(25), determined by targeted fnECHO between 6 and 12 hours of age.
|
|
E.4 | Principal exclusion criteria |
- Infants with major congenital anomalies including neural tube defects, major structural cardiac anomalies (excluding PDA/ASD/PFO), abdominal wall defects and congenital diaphragmatic hernia and major dysmorphic features with an abnormal karyotype e.g. T21, T13, T18. - The treating clinician does not intend to offer the infant intensive care. - Bidirectional shunt of PDA on ECHO (defined as shunt exceeding 30% of the right to left proportion of the shunting). - Grade II – IV IVH on point of care CRUSS on screening (between six to twelve hours of age). - PH prior to study commencement. - Severe PPHN. - History or examination suggestive of liver failure prior to study commencement. - Written informed consent has not been obtained before the infant is 12 hours of age, or the infant’s parent(s)/guardian(s) withdraw consent prior to commencement of the trial processes or assessments.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Combined outcome of periventricular/intraventricular haemorrhage (PIVH) ≥ grade II, NEC ≥ grade IIa (Bell's staging), and death before discharge. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• PDA closure rate • PDA exposure i.e. duration of time lived with PDA • Pulmonary haemorrhage (PH) • Spontaneous intestinal perforation (SIP) • Chronic Lung Disease of prematurity (CLD) (defined as need of oxygen and/or ventilatory support at 36 weeks of gestation) • Retinopathy of Prematurity (ROP) ≥grade III • Ventilation parameters during and after the study period • Use of inotropes during the study period • PDA medical treatment after the study period • PDA surgical treatment after the study period • Liver function tests • Neonatal pain score during the study period • Developmental outcome at two years corrected gestational age, as assessed by Bayley assessment will be carried out (ETAPA phase 3).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Each endpoint will be measured through the course of the trial, as outlined in the endpoint list in section E.5.2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be when all infants have been recruited and the last baby has been discharged from hospital, in order to ensure all secondary outcomes have been recorded. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |